Psychiatric Biomarker and Pharmacogenomics
- Research Opportunity
- PhD, Masters by Research, Honours
- Number of Honour Places Available
The Biomarker and Pharmacogenetic Research Program has a clinical orientation towards identifying biological markers relevant to psychiatric disorders and pharmacoresponse with an emphasis on mood disorders, cognitive function, and psychosis. The specific emphasis has been developed by studying the pharmacogenetic response to antidepressants as well as to electroconvulsive therapies in treatment resistant depression, pharmacogenetics of response to lithium treatment in bipolar disorder and an extensive biomarker project in clozapine treated patients is under way.
Functional genomics of major depressive disorder (MDD)
This study seeks to identify transcriptomic alterations in major depressive disorder (MDD) cases from a large locally recruited sample of participants exhibiting peripheral inflammation using next generation RNA sequencing technology.
Genomics of Electroconvulsive Therapy-International Consortium (GenECT-IC)
This study seeks to identify genomic, clinical and cognitive signatures of treatment response in severe depression treated with electroconvulsive therapy (ECT).
Pharmacogenomics of major depressive disorder (MDD)
This study investigates genomic and polygenic profiles to predict treatment response to antidepressants in depression.
Faculty Research Themes
School Research Themes
PhD, Masters by Research, Honours
Students who are interested in joining this project will need to consider their elegibility as well as other requirements before contacting the supervisor of this research
For further information about this research, please contact a supervisor.
MDHS Research library
Explore by researcher, school, project or topic.